Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Disposal

8 Feb 2010 07:00

RNS Number : 7954G
CareCapital Group plc
08 February 2010
 



8 February 2010

 

CARECAPITAL GROUP PLC

("CareCapital" or "the Company")

 

Sale of Part of UK Property Portfolio

 

CareCapital Group plc (AIM: CARE), the healthcare real estate developer and investor, announces that it has disposed of part of its UK property portfolio, comprising 14 primary care investment properties, through the sale of Sinclair Montrose Properties Limited ("SMP"), a wholly owned subsidiary of CareCapital (the "Disposal"), to Primary Health Investment Properties Limited ("PHP") for a consideration of £23.5 million payable in cash on completion.

 

The net cash proceeds, after the repayment of the senior debt within the SMP Group of Companies associated with these properties, will amount to approximately £4.4 million from which sum the majority of the Company's short term financing will be repaid with the balance to be used as working capital.

 

At 30 September 2009, the properties included in the Disposal were valued at £22.95 million as included in CareCapital's interim accounts. The properties' current rental income is £1.409 million per annum.

 

Additionally, CareCapital has entered into an agreement with PHP that provides for the funding and disposal on completion of further primary health care properties in CareCapital's development pipeline.

 

Dr Michael Sinclair, Chairman of CareCapital, commented: "This transaction has strengthened our balance sheet and provides a base from which to progress the opportunities in the remaining development pipeline. This pipeline, as previously disclosed, has a combined developed value of over £80 million.

 

"The Company's current development at Adlershof in Berlin, which is fully pre-let, is scheduled for completion next month and, combined with the existing Adlershof building, will provide one of the most important medical buildings in Germany with a total of over 8,000 square metres of space let to over 50 medical tenants. On completion of this building, the gross value of CareCapital's current portfolio of investment properties and completed developments will be approximately £34 million representing a net asset value for those assets in excess of £10.5 million."

 

For further information please visit www.carecapital.co.uk or contact:

 

CareCapital Group Plc

Daniel Stewart & Co. Plc

Tavistock Communications

 

 

Paul Stacey, Chief Executive

Steve Wilden, Finance Director

Simon Leathers

Simon Hudson

Paul Young

 

Tel: 020 7034 1949

Tel: 020 7776 6550

Tel: 020 7920 3150

 

pstacey@carecapital.co.uk

swilden@carecapital.co.uk

simon.leathers@danielstewart.co.uk

shudson@tavistock.co.uk

pyoung@tavistock.co.uk

 

-ends-

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DISKMGGZNNMGGZM
Date   Source Headline
27th Aug 20197:00 amRNSTotal Voting Rights and Directors' Shareholdings
8th Aug 201910:45 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Nearing the end-goal
7th Aug 20197:00 amRNSIssue of equity and new debt facility
6th Aug 201911:05 amRNSSecond Price Monitoring Extn
6th Aug 201911:00 amRNSPrice Monitoring Extension
25th Jul 20195:12 pmRNSResult of AGM
25th Jul 20197:00 amRNSAGM Statement & Technological update
22nd Jul 20197:00 amRNSHarley Street update
28th Jun 20197:00 amRNSFinal Results
3rd Jun 20197:00 amRNSTechnological update
31st May 20195:30 pmRNSTotal Voting Rights
17th May 20195:29 pmRNSHolding(s) in Company
16th May 20192:23 pmEQSAdvanced Oncotherapy (AVO-GB): Strong fundamentals underpin future growth
13th May 201912:20 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Commercialising a breakthrough technology
10th May 20197:00 amRNSDebt facility secured
16th Apr 201910:26 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Preparing for commercialisation
16th Apr 20199:12 amEQSAdvanced Oncotherapy (AVO-GB): Key talent acquisition reaffirms the promise of LIGHT
16th Apr 20197:00 amRNSSenior Management Appointment
7th Mar 20199:00 amRNSPrice Monitoring Extension
22nd Feb 20197:00 amRNSGrant of options
1st Feb 20197:00 amRNSAppointment of Nominated Adviser and Joint Broker
30th Jan 201911:45 amRNSSchedule 2(g) Disclosure
29th Jan 20199:38 amRNSTotal Voting Rights and Significant Shareholdings
24th Jan 201912:14 pmRNSSchedule 2(g) Disclosure
22nd Jan 20193:29 pmRNSResult of General Meeting
21st Jan 201911:15 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Important regulatory milestone: ISO approval
21st Jan 20197:00 amRNSISO 13485:2016 certification for medical devices
21st Dec 201810:15 amRNSLaunch of 2018 SAYE Scheme
21st Dec 20187:00 amRNSProposed Direct Subscription to raise £10.0m
16th Oct 20184:31 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Four components integrated
16th Oct 20183:58 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement
10th Oct 20187:30 amRNSGPSL Research - Flash Note on AVO
10th Oct 20187:00 amRNSTechnological update
4th Oct 201811:07 amRNSGPSL Research - Flash Note on AVO
28th Sep 20187:00 amRNSHalf-year Report
27th Sep 20187:00 amRNSTechnological update
10th Sep 201811:32 amRNSHolding(s) in Company
7th Sep 201811:52 amRNSHolding(s) in Company
3rd Sep 20185:15 pmEQSHardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement
3rd Sep 201811:38 amRNSCompletion of the £6.41m Placing
29th Aug 20189:57 amEQSHardman & Co Research: Advanced Oncotherapy (AVO): Treatment planning system agreement
28th Aug 20187:00 amRNSDirector Declaration
9th Aug 20187:00 amRNSExercise of Warrants and Issue of Shares
2nd Aug 20187:00 amRNS£6.41m Placing
25th Jul 20183:34 pmRNSResult of AGM
4th Jul 20184:40 pmRNSSecond Price Monitoring Extn
4th Jul 20184:35 pmRNSPrice Monitoring Extension
4th Jul 201811:05 amRNSSecond Price Monitoring Extn
4th Jul 201811:00 amRNSPrice Monitoring Extension
4th Jul 20189:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.